High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria

F. Kaneko, Hidekazu Suzuki, Naoki Hasegawa, K. Kurabayshi, Hidetsugu Saito, S. Otani, H. Nakamizo, K. Kawata, M. Miyairi, K. Ishii, H. Ishii

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Helicobacter pylori resistance to clarithromycin, probably due to the frequent use of this antibiotic for the treatment of other diseases, is the greatest obstacle against its eradication. Aim: To clarify the prevalence of clarithromycin-resistant H. pylori in patients with non-tuberculous myco-bacterial lung disease receiving multiple antibiotic treatment, including clarithromycin. Methods: We enrolled 88 patients with non-tuberculous mycobacterial lung disease; 29 underwent upper gastrointestinal endoscopy for the diagnosis of H. pylori infection prior to treatment, and 60 underwent it during treatment. The diagnosis of H. pylori infection was confirmed by histological examination, urease test and microaerobic bacterial culture. The minimum inhibitory concentration of clarithromycin was determined and the DNA was analysed for each of the isolated H. pylori strains. Results: Patients during the treatment had a high prevalence rate of clarithromycin-resistant H. pylori (100%). Analysis of DNA of the clarithromycin-resistant H. pylori isolates revealed point mutations at A2142G or A2143G. Moreover, a linear correlation was found between the total cumulative dose of clarithromycin and the minimum inhibitory concentration. Conclusion: All patients with non-tuberculous mycobacterial lung disease being treated long-term with multiple antibiotics, including clarithromycin, harboured clarithromycin-resistant H. pylori in the stomach. Therefore, eradication of H. pylori before commencement of long-term therapy including clarithromycin should be recommended.

Original languageEnglish
Pages (from-to)62-67
Number of pages6
JournalAlimentary Pharmacology and Therapeutics, Supplement
Volume20
Issue number1
Publication statusPublished - 2004 Jul

Fingerprint

Respiratory Therapy
Clarithromycin
Mycobacterium
Helicobacter pylori
Chronic Disease
Anti-Bacterial Agents
Lung Diseases
Microbial Sensitivity Tests
Helicobacter Infections
Therapeutics
Gastrointestinal Endoscopy
Urease
DNA
Point Mutation
Stomach

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. / Kaneko, F.; Suzuki, Hidekazu; Hasegawa, Naoki; Kurabayshi, K.; Saito, Hidetsugu; Otani, S.; Nakamizo, H.; Kawata, K.; Miyairi, M.; Ishii, K.; Ishii, H.

In: Alimentary Pharmacology and Therapeutics, Supplement, Vol. 20, No. 1, 07.2004, p. 62-67.

Research output: Contribution to journalArticle

@article{c5f0b34e60414e9abb1c37c301323e7c,
title = "High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria",
abstract = "Background: Helicobacter pylori resistance to clarithromycin, probably due to the frequent use of this antibiotic for the treatment of other diseases, is the greatest obstacle against its eradication. Aim: To clarify the prevalence of clarithromycin-resistant H. pylori in patients with non-tuberculous myco-bacterial lung disease receiving multiple antibiotic treatment, including clarithromycin. Methods: We enrolled 88 patients with non-tuberculous mycobacterial lung disease; 29 underwent upper gastrointestinal endoscopy for the diagnosis of H. pylori infection prior to treatment, and 60 underwent it during treatment. The diagnosis of H. pylori infection was confirmed by histological examination, urease test and microaerobic bacterial culture. The minimum inhibitory concentration of clarithromycin was determined and the DNA was analysed for each of the isolated H. pylori strains. Results: Patients during the treatment had a high prevalence rate of clarithromycin-resistant H. pylori (100{\%}). Analysis of DNA of the clarithromycin-resistant H. pylori isolates revealed point mutations at A2142G or A2143G. Moreover, a linear correlation was found between the total cumulative dose of clarithromycin and the minimum inhibitory concentration. Conclusion: All patients with non-tuberculous mycobacterial lung disease being treated long-term with multiple antibiotics, including clarithromycin, harboured clarithromycin-resistant H. pylori in the stomach. Therefore, eradication of H. pylori before commencement of long-term therapy including clarithromycin should be recommended.",
author = "F. Kaneko and Hidekazu Suzuki and Naoki Hasegawa and K. Kurabayshi and Hidetsugu Saito and S. Otani and H. Nakamizo and K. Kawata and M. Miyairi and K. Ishii and H. Ishii",
year = "2004",
month = "7",
language = "English",
volume = "20",
pages = "62--67",
journal = "Alimentary Pharmacology and Therapeutics, Supplement",
issn = "0953-0673",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria

AU - Kaneko, F.

AU - Suzuki, Hidekazu

AU - Hasegawa, Naoki

AU - Kurabayshi, K.

AU - Saito, Hidetsugu

AU - Otani, S.

AU - Nakamizo, H.

AU - Kawata, K.

AU - Miyairi, M.

AU - Ishii, K.

AU - Ishii, H.

PY - 2004/7

Y1 - 2004/7

N2 - Background: Helicobacter pylori resistance to clarithromycin, probably due to the frequent use of this antibiotic for the treatment of other diseases, is the greatest obstacle against its eradication. Aim: To clarify the prevalence of clarithromycin-resistant H. pylori in patients with non-tuberculous myco-bacterial lung disease receiving multiple antibiotic treatment, including clarithromycin. Methods: We enrolled 88 patients with non-tuberculous mycobacterial lung disease; 29 underwent upper gastrointestinal endoscopy for the diagnosis of H. pylori infection prior to treatment, and 60 underwent it during treatment. The diagnosis of H. pylori infection was confirmed by histological examination, urease test and microaerobic bacterial culture. The minimum inhibitory concentration of clarithromycin was determined and the DNA was analysed for each of the isolated H. pylori strains. Results: Patients during the treatment had a high prevalence rate of clarithromycin-resistant H. pylori (100%). Analysis of DNA of the clarithromycin-resistant H. pylori isolates revealed point mutations at A2142G or A2143G. Moreover, a linear correlation was found between the total cumulative dose of clarithromycin and the minimum inhibitory concentration. Conclusion: All patients with non-tuberculous mycobacterial lung disease being treated long-term with multiple antibiotics, including clarithromycin, harboured clarithromycin-resistant H. pylori in the stomach. Therefore, eradication of H. pylori before commencement of long-term therapy including clarithromycin should be recommended.

AB - Background: Helicobacter pylori resistance to clarithromycin, probably due to the frequent use of this antibiotic for the treatment of other diseases, is the greatest obstacle against its eradication. Aim: To clarify the prevalence of clarithromycin-resistant H. pylori in patients with non-tuberculous myco-bacterial lung disease receiving multiple antibiotic treatment, including clarithromycin. Methods: We enrolled 88 patients with non-tuberculous mycobacterial lung disease; 29 underwent upper gastrointestinal endoscopy for the diagnosis of H. pylori infection prior to treatment, and 60 underwent it during treatment. The diagnosis of H. pylori infection was confirmed by histological examination, urease test and microaerobic bacterial culture. The minimum inhibitory concentration of clarithromycin was determined and the DNA was analysed for each of the isolated H. pylori strains. Results: Patients during the treatment had a high prevalence rate of clarithromycin-resistant H. pylori (100%). Analysis of DNA of the clarithromycin-resistant H. pylori isolates revealed point mutations at A2142G or A2143G. Moreover, a linear correlation was found between the total cumulative dose of clarithromycin and the minimum inhibitory concentration. Conclusion: All patients with non-tuberculous mycobacterial lung disease being treated long-term with multiple antibiotics, including clarithromycin, harboured clarithromycin-resistant H. pylori in the stomach. Therefore, eradication of H. pylori before commencement of long-term therapy including clarithromycin should be recommended.

UR - http://www.scopus.com/inward/record.url?scp=4344694460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344694460&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 62

EP - 67

JO - Alimentary Pharmacology and Therapeutics, Supplement

JF - Alimentary Pharmacology and Therapeutics, Supplement

SN - 0953-0673

IS - 1

ER -